Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial - Concepedia

Concepedia

Publication | Open Access

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

DOI Full Paper Access

65

Citations

18

References

2023

Year

Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu,

Journal of Thoracic Oncology

Advanced Nonsquamous NsclcOncologyCamrelizumab Plus CarboplatinMedicineClinical TrialsCamel Phase 3Therapeutic EfficacyPharmacotherapyCancer TreatmentImmunotherapyPharmacologyNovel Therapy

References

	Year	Citations

Page 1

Page 1